Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Mar 21, 2018
Our Reports on Stocks in the Biotech Industry
Image Source: Celgene. This listing has been discontinued. Please see our reports on pharmaceutical stocks. Jul 30, 2014
Big Pharma Round Up
Let’s take a look at recent quarterly results from Big Pharma. Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings. Jan 27, 2014
Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space . Oct 11, 2013
Dividend Increases for the Week Ending October 11
Let's take a look at dividend increases for the week ending October 11. Jun 5, 2013
Three Very Good Questions From Members
We dig into three very good questions we’ve recently received from members about the Valuentum methodology. Dec 10, 2012
FAQ: How Often Does Valuentum Make Changes To Its Actively-Managed Portfolios?
We answer one of the most important questions behind the success of our process. Sep 24, 2012
Uncertainty Clouds Questcor Pharmaceuticals
A government probe and an insurance provider dropping coverage are leaving investors doubting the long-term viability of the firm's business. We remain on the sidelines. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
